How fast does primary lateral sclerosis (PLS) progress — and what can help predict that change? A new multicenter study found that PLS symptoms decline most rapidly early in the disease, and that neurofilament light (NfL), a blood biomarker linked to nerve damage, could help forecast progression. The research also validated the PLS Functional Rating Scale (PLSFRS), paving the way for more precise clinical trials. 🧠 UF Health Fixel Institute neurologist Dr. James Wymer was a contributing author on this important study. Read more about what this could mean for people living with PLS: onlinelibrary.wiley.com/doi/10.1002/ana.78056 #FixelInstitute #Neuroscience #PLS #NeuroResearch #UFHealth